Molecular pathology in neurodegenerative diseases

Current Drug Targets

Volumn 13, Issue 12, 2012, Pages 1548-1559

  Peden, Alexander H ^a   Ironside, James W ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Synuclein; A Protein; Neurodegeneration; Neurofibrillary tangles; Plaques; Prion protein; Proteinopathy; Tau protein

Indexed keywords

ALPHA SYNUCLEIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CEREBROSPINAL FLUID ANALYSIS; CORTICOBASAL DEGENERATION; DEGENERATIVE DISEASE; DISEASE SURVEILLANCE; FRONTOTEMPORAL DEMENTIA; GENETIC ANALYSIS; HUMAN; HUNTINGTON CHOREA; KENNEDY DISEASE; MOLECULAR PATHOLOGY; NERVE CELL DEGENERATION; NERVE CELL NECROSIS; NEUROFIBRILLARY TANGLE; PARKINSON DISEASE; PRION DISEASE; PROGRESSIVE SUPRANUCLEAR PALSY; REVIEW; RNA INTERFERENCE; SHY DRAGER SYNDROME; SPINOCEREBELLAR DEGENERATION; TAUOPATHY; TDP 43 PROTEINOPATHY; WESTERN BLOTTING;

ANIMALS; BIOLOGICAL MARKERS; CENTRAL NERVOUS SYSTEM; EARLY DIAGNOSIS; HUMANS; NERVE TISSUE PROTEINS; NEURODEGENERATIVE DISEASES; PATHOLOGY, MOLECULAR; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN FOLDING;

EID: 84870233530     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012803530134     Document Type: Review

References (109)

1. Sampson EL, Blanchard MR, Jones L, Tookman A, King M. Dementia in the acute hospital: prospective cohort study of prevalence and mortality. Br J Psychiatry 2009; 195: 61-66.
2. Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology 2009; 72: S1-136.
3. Winblad B, Jelic V. Long-term treatment of Alzheimer disease: efficacy and safety of acetylcholinesterase inhibitors. Alzheimer Dis Assoc Disord 2004; 18 Suppl 1: S2-S8.
4. Tolosa E, Wenning G, and Poewe W. The diagnosis of Parkinson's disease. Lancet Neurol 2006; 5: 75-86.
5. Otto M, Lewczuk P, Wiltfang J. Neurochemical approaches of cerebrospinal fluid diagnostics in neurodegenerative diseases. Methods 2008; 44: 289-298.
6. Seppala TT, Koivisto AM, Hartikainen P, Helisalmi S, Soininen H, Herukka SK. Longitudinal changes of CSF biomarkers in Alzheimer's disease. J Alzheimers Dis 2011; 25: 583-594.
7. Rabinovici GD, Miller BL. Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management. CNS Drugs 2010; 24: 375-398.
8. Ince PG, Highley JR, Kirby J, et al. Molecular pathology and genetic advances in amyotrophic lateral sclerosis: an emerging molecular pathway and the significance of glial pathology. Acta Neuropathol 2011; 122: 657-671.
9. Lee EB, Lee VM, Trojanowski JQ. Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. Nat Rev Neurosci 2011; 13: 38-50.
10. Gambetti P, Cali I, Notari S, Kong Q, Zou WQ, Surewicz WK. Molecular biology and pathology of prion strains in sporadic human prion diseases. Acta Neuropathol 2011; 121: 79-90
11. Parchi P, Strammiello R, Giese A, Kretzschmar H. Phenotypic variability of sporadic human prion disease and its molecular basis: past, present, and future. Acta Neuropathol 2011; 121: 91-112.
12. Stevens JC, Beck J, Lukic A, Ryan N, Abbs S, Collinge J, Fox NC, Mead S. Familial Alzheimer's disease and inherited prion disease in the UK are poorly ascertained. J Neurol Neurosurg Psychiatry 2011; 82: 1054-1057.
13. Forman MS, Farmer J, Johnson JK, et al. Frontotemporal dementia: clinicopathological correlations. Ann Neurol 2006; 59: 952-962.
14. Shah P, Lal N, Leung E, Traul DE, Gonzalo-Ruiz A, Geula C. Neuronal and axonal loss are selectively linked to fibrillar amyloid- {beta} within plaques of the aged primate cerebral cortex. Am J Pathol 2010; 177: 325-333.
15. Permanne B, Adessi C, Saborio GP, et al. Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with a beta-sheet breaker peptide. FASEB J 2002; 16: 860-862.
16. Lambert MP, Barlow AK, Chromy BA, et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998; 95: 6448-6453.
17. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 2007; 8: 101-102.
18. Lesne S, Koh MT, Kotilinek L, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006; 440: 352-357.
19. Li S, Jin M, Koeglsperger T, Shepardson NE, Shankar GM, Selkoe DJ. Soluble Abeta oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J Neurosci 2011; 31: 6627-6638.
20. Shankar GM, Li S, Mehta TH, et al. Amyloid-beta protein dimmers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008; 14: 837-842.
21. Giehm L, Svergun DI, Otzen DE, Vestergaard B. Low-resolution structure of a vesicle disrupting alpha-synuclein oligomer that accumulates during fibrillation. Proc Natl Acad Sci USA 2011; 108: 3246-3251.
22. Ayala YM, De Conti L, Avendano-Vazquez SE, et al. TDP-43 regulates its mRNA levels through a negative feedback loop. EMBO J 2011; 30: 277-288.
23. Liu-Yesucevitz L, Bilgutay A, Zhang YJ, et al. Tar DNA binding protein-43 (TDP-43) associates with stress granules: analysis of cultured cells and pathological brain tissue. PLoS One 2010; 5: e13250.
24. Olanow CW, McNaught KS. Ubiquitin-proteasome system and Parkinson's disease. Mov Disord 2006; 21: 1806-1823.
25. Sun F, Anantharam V, Zhang D, Latchoumycandane C, Kanthasamy A, Kanthasamy AG. Proteasome inhibitor MG-132 induces dopaminergic degeneration in cell culture and animal models. Neurotoxicology 2006; 27: 807-815.
26. Zhang L, Sheng R, Qin Z. The lysosome and neurodegenerative diseases. Acta Biochim Biophys Sin (Shanghai) 2009; 41: 437-445.
27. Nixon RA. Endosome function and dysfunction in Alzheimer's disease and other neurodegenerative diseases. Neurobiol Aging 2005; 26: 373-382.
28. Westermark GT, Westermark P. Prion-like aggregates: infectious agents in human disease. Trends Mol Med 2010; 16: 501-507.
29. Brundin P, Melki R, Kopito R. Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat Rev Mol Cell Biol 2010; 11: 301-307.
30. Frost B, Diamond MI. Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci 2010; 11: 155-159.
31. Schwab C, Arai T, Hasegawa M, Yu S, McGeer PL. Colocalization of transactivation-responsive DNA-binding protein 43 and huntingtin in inclusions of Huntington disease. J Neuropathol Exp Neurol 2008; 67: 1159-1165.
32. Kadokura A, Yamazaki T, Lemere CA, Takatama M, Okamoto K. Regional distribution of TDP-43 inclusions in Alzheimer disease (AD) brains: their relation to AD common pathology. Neuropathology 2009; 29: 566-573.
33. Uryu K, Nakashima-Yasuda H, Forman MS, et al. Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol 2008; 67: 555-564.
34. Jucker M, Walker LC. Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann Neurol 2011; 70: 532-540.
35. Krebs MR, Morozova-Roche LA, Daniel K, Robinson CV, Dobson CM. Observation of sequence specificity in the seeding of protein amyloid fibrils. Protein Sci 2004; 13: 1933-1938
36. Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science 1982; 216: 136-144.
37. Curril J, Chelle PL. Is the disease of scrapie inoculable? Comptes Rendus Hebdomadaires des Seances de l Academie des. Sciences 1936; 203: 1552-1554.
38. Ironside JW, McCardle L, Horsburgh A, Lim Z, Head MW. Pathological diagnosis of variant Creutzfeldt-Jakob disease. APMIS 2002; 110: 79-87.
39. Capellari S, Strammiello R, Saverioni D, Kretzschmar H, Parchi P. Genetic Creutzfeldt-Jakob disease and fatal familial insomnia: insights into phenotypic variability and disease pathogenesis. Acta Neuropathol 2011; 121: 21-37.
40. Will RG, Ironside JW, Zeidler M, et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996; 347: 921-925.
41. Bruce ME, Will RG, Ironside JW, et al. Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent. Nature 1997; 389: 498-501.
42. Scott MR, Will R, Ironside J, et al. Compelling transgenetic evidence for transmission of bovine spongiform encephalopathy prions to humans. Proc Natl Acad Sci USA 1999; 96: 15137-15142.
43. Telling GC. Transgenic mouse models and prion strains. Top CurrChem 2011; 305: 79-99.
44. Prusiner SB. Prions. Proc Natl Acad Sci USA 1998; 95: 13363-13383.
45. Riesner D. Biochemistry and structure of PrP(C) and PrP(Sc). Br Med Bull 2003; 66: 21-33
46. Griffith JS. Self-replication and scrapie. Nature 1967; 215: 1043-1044.
47. Soto C, Castilla J. The controversial protein-only hypothesis of prion propagation. Nat Med 2004; 10 Suppl: S63-S67.
48. Westergard L, Christensen HM, Harris DA. The cellular prion protein (PrP(C)): its physiological function and role in disease. Biochim Biophys Acta 2007; 1772: 629-644.
49. Zou WQ, Gambetti P. Prion: the chameleon protein. Cell Mol Life Sci 2007; 64: 3266-3270.
50. Raymond GJ, Hope J, Kocisko DA, et al. Molecular assessment of the potential transmissibilities of BSE and scrapie to humans. Nature 1997; 388: 285-288.
51. Saborio GP, Permanne B, Soto C. Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature 2001; 411: 810-813.
52. Castilla J, Saa P, Hetz C, Soto C. In vitro generation of infectious scrapie prions. Cell 2005; 121: 195-206.
53. Piening N, Weber P, Giese A, Kretzschmar H. Breakage of PrP aggregates is essential for efficient autocatalytic propagation of misfolded prion protein. Biochem Biophys Res Commun 2005; 326: 339-343.
54. Bieschke J, Weber P, Sarafoff N, Beekes M, Giese A, Kretzschmar H. Autocatalytic self-propagation of misfolded prion protein. Proc Natl Acad Sci USA 2004; 101: 12207-12211.
55. Saa P, Castilla J, Soto C. Ultra-efficient replication of infectious prions by automated protein misfolding cyclic amplification. J Biol Chem 2006; 281: 35245-35252.
56. Saa P, Castilla J, Soto C. Presymptomatic detection of prions in blood. Science 2006; 313: 92-94.
57. Jones M, Peden AH, Yull H, et al. Human platelets as a substrate source for the in vitro amplification of the abnormal prion protein (PrP) associated with variant Creutzfeldt-Jakob disease. Transfusion 2008; 49: 376-384.
58. Jones M, Peden AH, Head MW, Ironside JW. The application of in vitro cell-free conversion systems to human prion diseases. Acta Neuropathol 2011; 121: 135-143.
59. Tattum MH, Jones S, Pal S, Collinge J, Jackson GS. Discrimination between prion-infected and normal blood samples by protein misfolding cyclic amplification. Transfusion 2010; 50: 996-1002.
60. Colby DW, Zhang Q, Wang S, et al. Prion detection by an amyloid seeding assay. Proc Natl Acad Sci USA 2007; 104: 20914-20919.
61. Orru CD, Wilham JM, Raymond LD, et al. Prion disease blood test using immunoprecipitation and improved quaking-induced conversion. MBio 2011; 2: e00078-e000711.
62. Wilham JM, Orru CD, Bessen RA, et al. Rapid end-point quantitation of prion seeding activity with sensitivity comparable to bioassays. PLoS Pathog 2010; 6: e1001217.
63. Cosseddu GM, Nonno R, Vaccari G, et al. Ultra-efficient PrP(Sc) amplification highlights potentialities and pitfalls of PMCA technology. PLoS Pathog 2011; 7: e1002370.
64. Deleault NR, Harris BT, Rees JR, Supattapone S. From the Cover: Formation of native prions from minimal components in vitro. Proc Natl Acad Sci USA 2007; 104: 9741-9746.
65. Wang F, Wang X, Yuan CG, Ma J. Generating a prion with bacterially expressed recombinant prion protein. Science 2010; 327: 1132-1135.
66. Collinge J, Sidle KC, Meads J, Ironside J, Hill AF. Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD. Nature 1996; 383: 685-690.
67. Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 2004; 364: 527-529.
68. Peden A, McCardle L, Head MW, et al. Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia. Haemophilia 2010; 16: 296-304.
69. Gambetti P, Dong Z, Yuan J, et al. A novel human disease with abnormal prion protein sensitive to protease. Ann Neurol 2008; 63: 697-708.
70. Gambetti P, Puoti G, Zou WQ. Variably protease-sensitive prionopathy: a novel disease of the prion protein. J Mol Neurosci 2011; 45: 422-424.
71. Head MW, Lowrie S, Chohan G, Knight R, Scoones DJ, Ironside JW. Variably protease-sensitive prionopathy in a PRNP codon 129 heterozygous UK patient with co-existing tau, alpha synuclein and Abeta pathology. Acta Neuropathol 2010; 120: 821-823.
72. Parchi P, Strammiello R, Giese A, Kretzschmar H. Phenotypic variability of sporadic human prion disease and its molecular basis: past, present, and future. Acta Neuropathol 2011; 121: 91-112.
73. Cali I, Castellani R, Alshekhlee A, et al. Co-existence of scrapie prion protein types 1 and 2 in sporadic Creutzfeldt-Jakob disease: its effect on the phenotype and prion-type characteristics. Brain 2009; 132: 2643-2658.
74. Head MW, Bunn TJ, Bishop MT, et al. Prion protein heterogeneity in sporadic but not variant Creutzfeldt-Jakob disease: UK cases 1991-2002. Ann Neurol 2004; 55: 851-859.
75. Parchi P, Strammiello R, Notari S, et al. Incidence and spectrum of sporadic Creutzfeldt-Jakob disease variants with mixed phenotype and co-occurrence of PrPSc types: an updated classification. Acta Neuropathol 2009; 118: 659-6571.
76. Bishop MT, Will RG, and Manson JC. Defining sporadic Creutzfeldt-Jakob disease strains and their transmission properties. Proc Natl Acad Sci USA 2010; 107: 12005-12010.
77. Parchi P, Cescatti M, Notari S, et al. Agent strain variation in human prion disease: insights from a molecular and pathological review of the National Institutes of Health series of experimentally transmitted disease. Brain 2010; 133: 3030-3042.
78. Agrimi U, Nonno R, Dell'Omo G, et al. Prion protein amino acid determinants of differential susceptibility and molecular feature of prion strains in mice and voles. PLoS Pathog 2008; 4: e1000113.
79. Sailer A, Bueler H, Fischer M, Aguzzi A, Weissmann C. No propagation of prions in mice devoid of PrP. Cell 1994; 77: 967-968.
80. Brandner S, Isenmann S, Raeber A, et al. Normal host prion protein necessary for scrapie-induced neurotoxicity. Nature 1996; 379: 339-343.
81. White MD, Farmer M, Mirabile I, Brandner S, Collinge J, Mallucci GR. Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease. Proc Natl Acad Sci USA 2008; 105: 10238-10243.
82. Verity NC, Mallucci GR. Rescuing neurons in prion disease. Biochem J 2011; 433: 19-29.
83. Boudreau RL, Davidson BL. RNAi therapeutics for CNS disorders. Brain Res 2010; 1338: 112-121.
84. Silveira JR, Raymond GJ, Hughson AG, et al. The most infectious prion protein particles. Nature 2005; 437: 257-261.
85. Gibbs CJ, Jr., Amyx HL, Bacote A, Masters CL, Gajdusek DC. Oral transmission of kuru, Creutzfeldt-Jakob disease, and scrapie to nonhuman primates. J Infect Dis 1980; 142: 205-208.
86. Kim JI, Cali I, Surewicz K, et al. Mammalian prions generated from bacterially expressed prion protein in the absence of any mammalian cofactors. J Biol Chem 2010; 285: 14083-14087.
87. Mead S, Uphill J, Beck J, et al. Genome-wide association study in multiple human prion diseases suggests genetic risk factors additional to PRNP. Hum Mol Genet 2012; 21(8): 1897-1906.
88. Guerreiro RJ, Hardy J. Alzheimer's disease genetics: lessons to improve disease modelling. Biochem Soc Trans 2011; 39: 910-916.
89. Hardy J. Genetic analysis of pathways to Parkinson disease. Neuron 2010; 68: 201-206.
90. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006; 112: 389-404.
91. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med 2010; 362: 329-344.
92. Walsh DM and Selkoe DJ. A beta oligomers - a decade of discovery. J Neurochem 2007; 101: 1172-1184.
93. Weller RO, Subash M, Preston SD, Mazanti I, Carare RO. Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. Brain Pathol 2008; 18: 253-266.
94. Meyer-Luehmann M, Coomaraswamy J, Bolmont T, et al. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 2006; 313: 1781-1784.
95. Morales R, Duran-Aniotz C, Castilla J, Estrada LD, Soto C. De novo induction of amyloid-beta deposition in vivo. Mol Psychiatry 2011; [Epub ahead of print].
96. Li JY, Englund E, Holton JL, et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 2008; 14: 501-503.
97. Li JY, Englund E, Widner H, et al. Characterization of Lewy body pathology in 12- and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease. Mov Disord 2010; 25: 1091-1096.
98. Desplats P, Lee HJ, Bae EJ, et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alphasynuclein. Proc Natl Acad Sci USA 2009; 106: 13010-13015.
99. Volpicelli-Daley LA, Luk, KC, Patel TP, et al. Exogenous alphasynuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 2011; 72: 57-71.
100. Velayati A, Yu WH, Sidransky E. The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders. Curr Neurol Neurosci Rep 2010; 10: 190-198.
101. Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP- 43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006; 314: 130-133.
102. Arai T, Hasegawa M, Akiyama H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 2006; 351: 602-611.
103. Clavaguera F, Bolmont T, Crowther RA, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 2009; 11: 909-913.
104. Frost B, Jacks RL, Diamond MI. Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem 2009; 284: 12845-12852.
105. Frost B, Ollesch J, Wille H, Diamond MI. Conformational diversity of wild-type Tau fibrils specified by templated conformation change. J Biol Chem 2009; 284: 3546-35451.
106. Scherzinger E, Sittler A, Schweiger K, et al. Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology. Proc Natl Acad Sci USA 1999; 96: 4604-4609.
107. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 1993; 72: 971-983.
108. Gupta S, Jie S, Colby DW. Protein misfolding detected early in the pathogenesis of a transgenic mouse model of Huntington's disease using an amyloid seeding assay. J Biol Chem 2012; 87(13): 9982-9989
109. Will RG, Campbell MJ, Moss TH, Bell JE, Ironside JW. FFI cases from the United Kingdom. Brain Pathol 1998; 8: 562-563.